These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7606587)

  • 1. Clinical use of beta-lactamase inhibitors in combination with extended-spectrum penicillins.
    Jones RN
    Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S29-33. PubMed ID: 7606587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.
    Perry CM; Markham A
    Drugs; 1999 May; 57(5):805-43. PubMed ID: 10353303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
    Schoonover LL; Occhipinti DJ; Rodvold KA; Danziger LH
    Ann Pharmacother; 1995 May; 29(5):501-14. PubMed ID: 7655135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.
    Gin A; Dilay L; Karlowsky JA; Walkty A; Rubinstein E; Zhanel GG
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):365-83. PubMed ID: 17547502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of severe intra-abdominal infections: the role of piperacillin/tazobactam.
    Nord CE
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S35-8. PubMed ID: 7962987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection.
    Shlaes DM; Baughman R; Boylen CT; Chan JC; Charan NB; Cormier YC; Erickson A; Grossman R; Kirmani N; Suh B
    J Antimicrob Chemother; 1994 Oct; 34(4):565-77. PubMed ID: 7868408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.
    Appelbaum PC
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():29-38. PubMed ID: 8383654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections.
    Vestweber KH; Grundel E
    Eur J Surg Suppl; 1994; (573):57-60. PubMed ID: 7524797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
    Lister PD
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections.
    File TM; Tan JS
    Eur J Surg Suppl; 1994; (573):51-5. PubMed ID: 7524796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piperacillin-Tazobactam: a new beta-lactam-beta-lactamase inhibitor combination.
    Daniel KP; Krop LC
    Pharmacotherapy; 1996; 16(2):149-62. PubMed ID: 8820460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin/tazobactam in the treatment of polymicrobial infections.
    Gorbach SL
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S27-34. PubMed ID: 7962986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Bryson HM; Brogden RN
    Drugs; 1994 Mar; 47(3):506-35. PubMed ID: 7514977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
    Birawska I; Fuchs J; Szulakowska E
    Med Dosw Mikrobiol; 1998; 50(1-2):41-6. PubMed ID: 9857612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piperacillin/tazobactam: a critical review of the evolving clinical literature.
    Sanders WE; Sanders CC
    Clin Infect Dis; 1996 Jan; 22(1):107-23. PubMed ID: 8824974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
    Eklund AE; Nord CE
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.